Research programme: Neoantigen-specific adoptive T cell therapies - Likang Life Sciences
Alternative Names: LK Neo ACT; LK-Neo ACT - Likang Life SciencesLatest Information Update: 31 Mar 2023
At a glance
- Originator Likang Life Sciences
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Mar 2023 Preclinical trials in Cancer in China (Parenteral) prior to March 2023 (Likang Life Sciences pipeline, March 2023)